anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
Prior studies have suggested that immune thrombotic thrombocytopenic purpura (iTTP) may display seasonal variation; however, methodologic limitations and sample sizes have diminished the ability to perform a rigorous assessment. This 5-year retrospective study assessed the epidemiology of iTTP and determined whether it displays a seasonal pattern. Patients with both initial and relapsed iTTP (defined as a disintegrin and metalloprotease with thrombospondin type motifs 13 activity <10%) from 24 tertiary centers in Australia, Canada, France, Greece, Italy, Spain, and the US were included. Seasons were defined as: Northern Hemisphere-winter (December-February); spring (March-May); summer (June-August); autumn (September-November) and Southern Hemisphere-winter (June-August); spring (September-November); summer (December-February); autumn (March-May). Additional outcomes included the mean temperature in months with and without an iTTP episode at each site. A total of 583 patients experienced 719 iTTP episodes. The observed proportion of iTTP episodes during the winter was significantly greater than expected if equally distributed across seasons (28.5%, 205/719, 25.3%-31.9%; p = .03). Distance from the equator and mean temperature deviation both positively correlated with the proportion of iTTP episodes during winter. Acute iTTP episodes were associated with the winter season and colder temperatures, with a second peak during summer. Occurrence during winter was most pronounced at sites further from the equator and/or with greater annual temperature deviations. Understanding the etiologies underlying seasonal patterns of disease may assist in discovery and development of future preventative therapies and inform models for resource utilization.
The present application discloses compositions and methods of synthesis and use of F-18 labeled molecules of use, for example, in PET imaging techniques. In particular embodiments, the labeled molecules may be peptides or proteins, although other types of molecules including but not limited to aptamers, oligonucleotides and nucleic acids may be labeled and utilized for such imaging studies. In preferred embodiments, the F-18 label may be conjugated to a targeting molecule by formation of a metal complex and binding of the F-18-metal complex to a chelating moiety, such as DOTA, NOTA, DTPA, TETA or NETA. In other embodiments, the metal may first be conjugated to the chelating group and subsequently the F-18 bound to the metal. In other preferred embodiments, the F-18 labeled moiety may comprise a targetable conjugate that may be used in combination with a bispecific or multispecific antibody to target the F-18 to an antigen expressed on a cell or tissue associated with a disease, medical condition, or pathogen. Exemplary results show that F-18 labeled targetable conjugate peptides are stable in human serum at 37° C. for several hours, sufficient time to perform PET imaging analysis.
It has been determined that ingested vitamin B12 is bound by R protein in gastric juice, but that it is not capable of absorption in this form. In a system with a normally functioning exocrine pancreas, R protein is degraded by pancreatic proteases in the small intestine, which then allows the B12 to be transferred and bound to intrinsic factor protein (IF) from which it can be absorbed. This phenomenon serves as the basis for a test for pancreatic exocrine function in which the following compositions are ingested: (1) a complex of IF and B12 in which the B12 is labelled; (2) a combination of another binding material, such as R protein, and B12, in which the B12 is labelled (in preferred embodiments the B12 is labelled differently than the B12 in the IF-B12 complex); and (3) means for preventing R protein in the gastric juices from removing B12 from the IF-B12 complex, (in preferred embodiments such means are B12 analogues that bind to R protein in the gastric juices; but which do not bind to IF). In preferred embodiments of the test, unbound IF is also ingested. As a part of the preferred process, steps are also taken to tie up B12 binding proteins which are normally in the test subject"s blood and plasma. Subsequently, the subject"s excreted urine is measured for the amount of labelled B12 which was originally ingested as IF-B12 and for the amount of B12 originally bound to the other binding material, such as R-B12. The amount of B12 from each source which is excreted in the urine, and the ratio between them, is indicative of the functioning of the subject"s exocrine pancreas. Other aspects of the present invention include compositions containing combinations of test compositions. Yet another aspect of the invention is provided by methods of making several of the test compositions and the resulting products.
Clinical heterogeneity and varied prognosis are well noted for SARS-CoV-2 infection. Altered immune response is a major feature for the adverse prognosis however focus on altered immune response has been primarily limited to hyper-inflammatory responses like Cytokine storm. A deeper understanding of viral pathobiology and the interplay of innate and adaptive immune cells against SARS-CoV-2 infection is essential to optimize intervention strategy and future preparedness for SARS-CoV-2 or its related viral diseases. To uncover the immunological signatures driving the progression of SARS-CoV-2 infection, we performed an extensive immunophenotype on blood samples from 79 hospitalized patients with mild/moderate to severe infections as well as from healthy controls and recovered donors to understand the interplay between innate and adaptive responses impacting severity and prognosis. We observed multifarious immune dysregulation, varied across patients of the clinical spectrum. We observed 4 major dysregulations of immune phenotypes 1) depletion of M1φ (impaired antiviral response as APC), 2) immune suppression/exhaustion via activation of repressor like CD4+/CD8+PD1, TIM3, LAG3 3) inappropriate differentiation of lymphocyte (extreme elevated proportion of CD4 naive, memory B and T cells along with reduction of inflammatory activator like TLR2/4/TIGIT) and 4) cytokine storm. Our results show the identification of biomarkers to differentiate the different trajectories for SARS-CoV-2 infection.
Body image disturbance is closely linked to eating disorders including anorexia nervosa (AN). Distorted body image perception, dissatisfaction and preoccupation with weight and shape are often key factors in the development and maintenance of these disorders. Although the pathophysiological mechanism of body image disorder is not yet fully understood, aberrant biological processes may interfere with perceptive, cognitive and emotional aspects of body image. This study focuses on the neurobiological aspects of body image disturbance. The sample consisted of 12 adolescent girls diagnosed with AN, nine girls with major depressive disorder (MDD) and 10 without psychiatric diagnoses (HC, the healthy control group). We applied a block-design task in functional magnetic resonance imaging using participants' original and distorted overweight and underweight images. After imaging, the participants scored the images for resemblance, satisfaction and anxiety levels. The findings of this study demonstrate that overweight images elicited dissatisfaction and increased occipitotemporal activations across all participants. However, no difference was found between the groups. Furthermore, the MDD and HC groups showed increased activations in the prefrontal cortex and insula in response to underweight images compared to their original counterparts, whereas the AN group exhibited increased activations in the parietal cortex, cingulate gyrus and parahippocampal cortex in response to the same stimuli.
Patients receive danvatirsen IV over 1 hour on days 7, 5 and 3 prior to cycle 1, then on days 1, 8, 15 and 22. Patients also receive durvalumab IV over 1 hour on day 1. Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity.
Participants will receive a single dose of Test GXR RM tablet on Day 1 in treatment period 1 followed by a single dose of Reference GXR RM tablet on Day 8 in treatment period 2 under fed condition. There will be separate washout period of 7 days between each treatment period.
All eligible participants will receive secukinumab 300 mg s.c. (2 x 150mg/1mL PFS secukinumab) from baseline and every 4 weeks up to 2 years. The study medication may be modified/adjusted after the initial doses of 300mg s.c. (decreased to 150mg s.c. q4w or increased again from 150mg s.c. q4w to 300mg s.c. q4w) if deemed appropriate by the investigator. Dose modification/adjustment may only occur from Week 24 visit onwards. The modification/adjustment of the study medication will be determined at a site visit.
Enrolled subjects will receive FICB with 50cc of 0.3% ropivacaine. Blocks will be performed intra-operatively under direct surgeon visualization, in the operating room.
<P>PROBLEM TO BE SOLVED: To provide a system, program, and method capable of consolidating clinical study data and determining optimal administration while managing duration of administration.  <P>SOLUTION: Patients are chosen and temporarily registered with their consent (S1), whose data are transmitted to a data center by a doctor. Just a basic drug is administered to the patients over a predetermined period to collect their blood pressure data. In a first stage, the basic drug and allocated drug are concomitantly administered to the patients whose blood pressures have not reached a target value for lower pressure. In a second stage, the more basic drug is administered to the patients whose blood pressures have not reached the target value. In a third stage, the more allocated drug is administered to the patients whose blood pressures have not reached the target value. Other antihypertensive drugs prescribed by the doctor are administered to the patients whose blood pressures have not reached the target value (S4). Information on each administration is sent to a terminal of the data center by a server that holds data of plurality of medical institutions, which provides interavailability of the medical data.  <P>COPYRIGHT: (C)2006,JPO&NCIPI
BACKGROUND: Micheliolide (MCL), which is the active metabolite of parthenolide, has demonstrated promising clinical application potential. However, the effects and underlying mechanisms of MCL on atherosclerosis are still unclear.
METHOD: ApoE-/- mice were fed with high fat diet, with or without MCL oral administration, then the plaque area, lipid deposition and collagen content were determined. In vitro, MCL was used to pretreat macrophages combined by ox-LDL, the levels of ferroptosis related proteins, NRF2 activation, mitochondrial function and oxidative stress were detected.
RESULTS: MCL administration significantly attenuated atherosclerotic plaque progress, which characteristics with decreased plaque area, less lipid deposition and increased collagen. Compared with HD group, the level of GPX4 and xCT in atherosclerotic root macrophages were increased in MCL group obviously. In vitro experiment demonstrated that MCL increased GPX4 and xCT level, improved mitochondrial function, attenuated oxidative stress and inhibited lipid peroxidation to suppress macrophage ferroptosis induced with ox-LDL. Moreover, MCL inhibited KEAP1/NRF2 complex formation and enhanced NRF2 nucleus translocation, while the protective effect of MCL on macrophage ferroptosis was abolished by NRF2 inhibition. Additionally, molecular docking suggests that MCL may bind to the Arg483 site of KEAP1, which also contributes to KEAP1/NRF2 binding. Furthermore, Transfection Arg483 (KEAP1-R483S) mutant plasmid can abrogate the anti-ferroptosis and anti-oxidative effects of MC in macrophages. KEAP1-R483S mutation also limited the protective effect of MCL on atherosclerosis progress and macrophage ferroptosis in ApoE-/- mice.
CONCLUSION: MCL suppressed atherosclerosis by inhibiting macrophage ferroptosis via activating NRF2 pathway, the related mechanism is through binding to the Arg483 site of KEAP1 competitively.
A micromolecular organic method based on the mixed application of different active ingredients to provide an excellent corrective effect of the aesthetic and cosmetic alterations typical of aging. The active ingredients have synergistic effects, which potentiates or increases the effect on each other due the method of their combination. In addition to maintaining the good results achieved for a long time, the formulations, quantities, concentrations, sequencing, synergy, potentiation, amplification of effects, spatial structure effects relationship, form of administration, etc. present a wide margin of tolerance to the skin. The method including applying a BioNutrient MBM, a BioGel MBM, a BioExfoliant No. 1, a BioExfoliant No. 2, a cleaning mask, a face cleaner, a deep cleaner, a moisturizing lotion No. 1, a SPF lotion, a moisturizing lotion No. 2 with soothing effect and AntiSpot lotion to skin.
PURPOSE:To provide the subject low irritant and low toxic absorption accelerating agent containing a specific polyorganosiloxane and having a good percutaneous absorption-accelerating activity for medicines. CONSTITUTION:The objective absorption-accelerating agent contains a polyorganosiloxane having a carboxylic acid residue at one molecular end and represented by formula I (R<1>-R<5> are 1-6C alkyl, phenyl; A is 2-13C divalent alkylene or divalent alkylene bonded to a methylenephenylene; n is 1 or larger) or formula II (M is alkali metal). The compound of formula I is obtained e.g. by reacting a polyorganosiloxane having a halomethylphenyl group at one molecular end and represented by formula III with water and carbon monoxide in the presence of a group VIII transition metal element and a base. The compound of formula II is also obtained by reacting the compound of formula I with an alkali metal hydroxide. The absorption-accelerating agent is dissolved together with a medicine to be administered in a solvent such as water or an alcohol and subsequently added to a tinctura, an ointment, etc.
The Mind intervention uses the evidence-based BrainHQ computerized cognitive training program. BrainHQ focuses on improving memory, attention, sensory function, and working memory, and has demonstrated efficacy in improving memory among healthy older adults and adults with heart failure. BrainHQ is tailored to the individual, and program difficulty automatically progresses based on performance. Training occurs during three 30-minute sessions per week, for a total of 36 hours. Participants will complete the BrainHQ program on an iPad tablet, which will be provided to them.
This is a randomized, double-blind, placebo-controlled prospective study to assess the influence and efficacy of intramuscular (IM) Botulinum Toxin Type A (BTA) injection in patients with painful hallux valgus with the use of total contact insole.

Fifty feet with painful hallux valgus will be collected. Informed consent is obtained according to the hospital's medical ethics and the human clinical trial committee. The feet will be randomized into 2 groups: Group A (n=25, treatment group) and Group B (n=25, control group). Clinical diagnosis of hallux valgus is made based on observation of great toe lateral deviation. Inclusion criteria were hallux valgus with angle of at least 20°, single or bilateral hallux valgus. To obtain the hallux valgus angle, foot roentgenography in AP and sesamoid views under the weight bearing condition will be obtained. The angle formed by lines drawn to bisect the first metatarsal bone and the proximal phalanx of the great toe will be measured. The exclusion criteria include history of foot operations, rheumatoid and gouty arthritis, and any contraindication to BTA administration. Subjective data such as the Foot Function Index will be collected.
The invention discloses a medicine which is prepared by the Chinese herbs with the functions of clearing away the heart fire and eliminating phlegm, sedation and decompression and is used for treating high blood pressure. The medicine is a refined external-use compound paste prepared by the effective ingredients of Radix Stephaniae Tetrandrae, Radix Astragali, Radix Rehmanniae Preparata, Rhizoma Diosscoreae, Fructus Corni, Rhizoma Alismatis,  Radix Paeoniae Alba, Poria, Cortex Moutan, Radix Salviae Miltiorrhizae and Euonymus alatus. The invention has evident effect on decompression, sedation and diuresis. The paste body of the plaster is fine, soft and smooth, easy to be coated on cloth and uneasy to melt, easy for carrying and use because of small size, and good for quick recovery of focus. The poultice has stable drug property and has the characteristics of quick percutaneous absorption, good ventilation property and gradual drug releasing. Compared with the oral preparation, the invention has the advantages of no liver-intestines first-filter action, no influence from gastrointestinal degradation and high bioavailability. Compared with injection, the invention has the advantages of convenient use and no pain. Compared with ointment, the invention has the advantages of accurate dose and fixed absorption area. Compared with black plaster and sticking plaster, the invention has the advantages of no sensibility on skin, no pollution to clothes, long effect, percutaneous absorption and convenient carrying and use.
HEMANGEOL prevents the response of endogenous catecholamines to correct hypoglycemia and masks the adrenergic warning signs of hypoglycemia, particularly tachycardia, palpitations and sweating. HEMANGEOL can cause hypoglycemia at any time during treatment. Risk is increased during a fasting period (e.g., poor oral food intake, infection, vomiting) or when glucose demands are increased (e.g., cold, stress, infections). Withhold the dose under these conditions. Hypoglycemia may present in   
the form of seizures, lethargy, or coma. Discontinue HEMANGEOL if hypoglycemia develops and treat appropriately Concomitant treatment with corticosteroids may increase the risk of hypoglycemia [ see Drug Interactions (7) ] .
Participants identified as having a moderate to high risk of suicide based on ISP screening will then be randomized. Participants randomized to the MINDBODYSTRONG© program (intervention) will receive the 8-session online interactive program. Reminders will be sent weekly to complete the next MINDBODYSTRONG© session and a MINDBODYSTRONG© trained coach will check in with participants by phone at baseline, weeks 3 and 5 of the on-line program to reinforce key program concepts and assess whether participants are completing the weekly skills building activities. Nurses assigned to the control group will only receive the mISP alone (aforementioned) and will be contacted for follow-up surveys.
The subjects who completed colorectal cancer polygene methylation test at baseline, and those with negative test results (n= 500, direct extraction method) completed colonoscopy within 3 months. The end points and follow-up were the same as those in the positive group. The negative group was compared with the positive group to observe the difference of negative predictive value and survival outcome.
A process for delivering hair removal fluids to hair ducts. In a preferred embodiment the fluid is a vaccine for slowing or stopping hair growth and a process for applying the vaccine or other hair growth vaccines to the skin region having unwanted hair and a method of delivering the vaccine to skin regions of unwanted hair. The preferred vaccine consists of an antigen cocktail of weakened or essentially dead elements of hair follicles for stimulating antibody responses. The preferred vaccine is prepared from patient's own hair papilla or bulge area stem cells. In other embodiments vaccines are made from extracts of papilla cells cultivated in a laboratory. The vaccines produce antibodies and these antibodies attack and destroy hair papilla and block bulge area cells that would otherwise produce or stimulate a growth of new papilla cells.
Objective: To understand the current status of occupational exposure to dust or harmful gases and occupational protection in people aged ≥40 years in China, and provide data support for the prevention and control of occupational dust or harmful gas exposure. Methods: The data were obtained from the surveillance for chronic obstructive pulmonary disease (COPD) in adults aged ≥40 years selected by multi-stage stratified cluster sampling from 125 surveillance points in 31 provinces (autonomous regions and municipalities) during 2014-2015 and 2019-2020, and relevant information about occupational dust or harmful gas exposure and protection measures were collected through face-to-face interviews. Occupational dust or harmful gas exposure rate and occupational protection rate were estimated by using weighting complex sampling methods, and then the results were compared. Results: From 2014 to 2015 and from 2019 to 2020, a total of 71 061 and 71 023 individuals aged ≥40 years were surveyed, respectively. The rate of occupational exposure to dust or hazardous gas was 33.8% (95%CI: 29.9%-37.7%) during 2019-2020. The occupational exposure rate was higher in men than in women and in rural residents than in urban residents. With the increase of education level, the rate of occupational exposure to dust or harmful gas showed a downward trend. The protection rate against occupational dust or hazardous gas exposure was 47.9% (95%CI: 43.2%-52.6%) during 2019-2020. Compared with 2014-2015, the rate of occupational exposure to dust or hazardous gas decreased by 10.7 percentage points in different gender, area and occupational groups and the occupational protection rate increased by 21.9 percentage points during 2019-2020. The decrease in occupational exposure rate was higher in western China than in eastern and central China, and the increase in occupational protection rate was higher in western China than in eastern and central China. Conclusions: The rate of occupational exposure to dust or harmful gas decreased and the rate of occupational protection against dust or harmful gas exposure increased in China during 2019-2020. However, about one-third of the population still suffer from the occupational exposure, and less than half of them take protection measures. It is necessary to pay more attention to the key populations, such as workers with lower cultural level and rural migrant workers, in occupational health practice.
An Application Factory system and method with a Composition Studio, where a workflow for a Device Application or Component is generated from user-initiated selections of at least one of a logic and data element from an Event, Logic, Data, Math, Workflow, or Service Palette, and a user interaction element from a Graphic, Widget, Audio/Video, or Haptic Palette. The workflow is displayed on a Data and Logic Canvas or Multimedia User Interaction Canvas of a user device. A Build Engine supports compilation of the Device Application or Component. And a Generic Device Model provides testing of the Device Application or Component. A Distribution Center provides at least one of discovery of, education on, demonstration of, experimentation with, and acquisition of the Device Application or Component. The Composition Studio utilizes a Visual and XML-Based Representation Language to enable the workflow to be generated without the user having to perform software coding.
Stress echocardiography has become a valuable technique for the non-invasive detection of coronary artery disease (CAD). Its accuracy has been shown to be superior to that of the exercise electrocardiogram and comparable to that of myocardial perfusion imaging. Myocardial contrast echocardiography (MCE) offers the potential to evaluate tissue perfusion at the level where oxygen transfer to the myocytes occurs. MCE can, therefore, provide information regarding the functional status of the myocardial microvasculature and presence of blood flow disparity. The purpose of this study is to evaluate the accuracy of MCE compared to stress echocardiography. We will correlate these results with findings from coronary angiography and compare the ability of those techniques to detect CAD.